EUVIMEDEUVIMED entdecken
Open Access

Tuberculosis Preventive Treatment for Pregnant People With HIV in South Africa: A Modeling Analysis of Clinical Benefits and Risks

Linzy V Rosen, Acadia M Thielking, Caitlin M Dugdale iD, Grace Montepiedra iD, Emma Kalk iD, Soyeon Kim iD, Sylvia M LaCourse iD, Jyoti S Mathad iD, Kenneth A Freedberg iD, C Robert Horsburgh iD, A David Paltiel iD, Robin Wood iD und 2 weitere

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciae508 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Linzy V Rosen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Tuberculosis, HIV Infections, Antitubercular Agents, Pregnancy Complications, Infectious. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: FIC NIH HHS, NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although prior studies of tuberculosis-preventive treatment (TPT) for pregnant people with human immunodeficiency virus (PPWH) report conflicting adverse pregnancy outcome (APO) risks, international guidelines recommend TPT for PPWH.

Methods

We used a microsimulation model to evaluate 5 TPT strategies among PPWH receiving antiretroviral therapy in South Africa: No TPT; 6 months of isoniazid (6H) or 3 months of isoniazid-rifapentine (3HP) during pregnancy (Immediate 6H or Immediate 3HP) or post partum (Deferred 6H or Deferred 3HP). The primary outcomes were maternal, fetal/infant, and combined deaths from causes potentially influenced by TPT (maternal tuberculosis, maternal hepatotoxicity, stillbirth, low birth weight [LBW], and infant tuberculosis). Tuberculosis during pregnancy confers 250% and 81% higher modeled risks of stillbirth and LBW, respectively. In lower-risk or higher-risk scenarios, immediate TPT confers 38% lower or 92% higher risks of stillbirth and 16% lower or 35% higher risks of LBW.

Results

Immediate TPT would minimize deaths among PPWH. When TPT confers higher stillbirth and LBW risks, immediate TPT would produce the most combined maternal and fetal/infant deaths, even with low maternal CD4 cell count and high tuberculosis incidence. If immediate TPT yields a <4% or <20% increase in stillbirth or LBW, immediate TPT would produce fewer combined deaths than deferred TPT (sensitivity analysis range, <2%–22% and <11%–120%, respectively).

Conclusions

If APO risks are below identifiable thresholds, TPT during pregnancy could decrease combined maternal and fetal/infant deaths. Given uncertainty around isoniazid's risks, and the low threshold at which APO risks could outweigh benefits from tuberculosis deaths averted, studies of newer TPT regimens among PPWH are warranted to inform guidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TuberculosisHIV InfectionsAntitubercular AgentsPregnancy Complications, InfectiousHumansFemalePregnancySouth AfricaIsoniazidInfant, NewbornAdultRifampinPregnancy OutcomeRisk AssessmentChemopreventionAnti-HIV Agents

Stichwörter der Autor:innen

HIVadverse pregnancy outcomepregnancytuberculosistuberculosis preventive treatment

Substanzen

Antitubercular AgentsIsoniazidRifampinrifapentineAnti-HIV Agents

Autor:innen und Institutionen

  • Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Centre for Infectious Disease Epidemiology and Research, School of Public Health, Faculty of Health Sciences, University of Cape Town, Cape Town, Western Cape, South Africa.
  • Frontier Science Foundation, Brookline, Massachusetts, USA.

ORCID-Profile: Caitlin M Dugdale, Grace Montepiedra, Emma Kalk, Soyeon Kim, Sylvia M LaCourse, Jyoti S Mathad, Kenneth A Freedberg, C Robert Horsburgh, A David Paltiel, Robin Wood, Andrea L Ciaranello, Krishna P Reddy

Förderung

  • FIC NIH HHS
  • NIH HHS
  • NIAID NIH HHS
  • MGH James and Audrey Foster Research Scholar Award
  • NICHD NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • Fogarty International Center

Zitieren

APA

Rosen, L. V., Thielking, A. M., Dugdale, C. M., Montepiedra, G., Kalk, E., Kim, S., LaCourse, S. M., Mathad, J. S., Freedberg, K. A., Horsburgh, C. R., Paltiel, A. D., Wood, R., Ciaranello, A. L., & Reddy, K. P. (2025). Tuberculosis Preventive Treatment for Pregnant People With HIV in South Africa: A Modeling Analysis of Clinical Benefits and Risks. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae508

Vancouver

Rosen LV, Thielking AM, Dugdale CM, Montepiedra G, Kalk E, Kim S, et al. Tuberculosis Preventive Treatment for Pregnant People With HIV in South Africa: A Modeling Analysis of Clinical Benefits and Risks. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae508

BibTeX
@article{Rosen2025,
  author = {Rosen, Linzy V and Thielking, Acadia M and Dugdale, Caitlin M and Montepiedra, Grace and Kalk, Emma and Kim, Soyeon and LaCourse, Sylvia M and Mathad, Jyoti S and Freedberg, Kenneth A and Horsburgh, C Robert and Paltiel, A David and Wood, Robin and Ciaranello, Andrea L and Reddy, Krishna P},
  title = {Tuberculosis Preventive Treatment for Pregnant People With HIV in South Africa: A Modeling Analysis of Clinical Benefits and Risks},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciae508}
}
Kostenlos starten →